Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria.
about
Protection from endotoxic shock by EVK-203, a novel alkylpolyamine sequestrant of lipopolysaccharideDrug Carriers: Not an Innocent Delivery ManLipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomosperminesCombination of antimicrobial and endotoxin-neutralizing activities of novel oleoylamines.Anti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide-recognizing motifs in small moleculesTherapeutic interventions in sepsis: current and anticipated pharmacological agentsAnti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents.Structure-activity relationships of lipopolysaccharide sequestration in guanylhydrazone-bearing lipopolyamines.Zwitterionic chitosan for the systemic treatment of sepsis.Association of glycemic profiles with whole blood polyamine among middle-aged Japanese men: colorimetric assay using oat and barley seedling polyamine oxidase.Marine compounds with therapeutic potential in gram-negative sepsis.Structure-activity relationships of lipopolysaccharide sequestration in N-alkylpolyamines.Structural correlation between lipophilicity and lipopolysaccharide-sequestering activity in spermine-sulfonamide analogs.Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines.Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock.Polyethylenimine-dermatan sulfate complex, a bioactive biomaterial with unique toxicity to CD146-positive cancer cells.Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation.Recent advances in nanomedicine for sepsis treatment.
P2860
Q24676683-F653CA05-35CE-4382-B21C-E1F317E0E53BQ28082414-2C816B7E-9088-4AC9-BC48-2AF084ACAC23Q30476710-7960ADE8-27C1-49BC-97C5-92991736DBADQ33836526-DD6F8F8E-8FB0-4C7C-9E1E-C699AFA4F0B2Q34333751-66E01061-E1DB-40FA-BC12-DF87EB6B553DQ34427050-80E09E8B-0B6F-44D7-917E-87BE403AA634Q34977410-5F8EC228-812C-4263-924F-E24B8C255DA9Q36984710-4CDE55D2-2450-4A36-9E02-DF62977608F5Q37093311-C202163F-5268-4E12-B5C6-7D64648EACB0Q37232228-01D67365-2C90-4B72-80E9-6D5BE2AC9D06Q38115689-8A40CA54-34DD-4736-BC2A-2632843ED2E0Q39866380-AF377A4C-4505-4BD7-8FD7-F34A8ED2D236Q41544081-40BE0D4A-260E-4F6F-A363-F661C2553BA1Q41578633-33C30FAA-A09A-4540-889C-031BFD40CC50Q43260803-5D5E6D26-131F-4B19-84E8-6CB47F9EEEC1Q44743745-FC17B30B-9587-43E0-9461-CF0F4D7F1590Q49864679-8BA23C6B-D854-4567-BCE7-C704767CA334Q52315864-C15C45C7-E96C-4753-B5D8-FA7A44F12B72Q54222088-2509133D-AFD8-497B-B05E-8DFD5352FA06
P2860
Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@ast
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@en
type
label
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@ast
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@en
prefLabel
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@ast
Lipopolyamines: novel antiendo ...... sed by gram-negative bacteria.
@en
P2093
P2860
P356
P1476
Lipopolyamines: novel antiendo ...... used by gram-negative bacteria
@en
P2093
D C Morrison
R Silverstein
P2860
P304
P356
10.1128/AAC.43.4.912
P407
P577
1999-04-01T00:00:00Z